ArticleScientific reports2020
Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.JAMA ophthalmology · 2022Pooled it
- Faricimab versus Aflibercept for Discharge and Readmission in Neovascular Age-Related Macular Degeneration: A Lesion-Type Stratified, Real-World UK Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab.International journal of retina and vitreous · 2025Article
- Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration.The British journal of ophthalmology · 2025Review
- Non-exudative OCT findings in neovascular AMD.Eye (London, England) · 2025Review
- First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2025Observational
- OCT predictors of retinal atrophy in neovascular age-related macular degeneration treated with aflibercept.International journal of ophthalmology · 2025Article
- Review of Guideline Recommendations for Optimal Anti-VEGF Therapy in Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2024Review
- Fluid Biomarkers in Optical Coherence Tomography for Visual Outcome in Polypoidal Choroidal Vasculopathy.Journal of personalized medicine · 2024Article
- Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration.Scientific reports · 2024Article
- AI-based support for optical coherence tomography in age-related macular degeneration.International journal of retina and vitreous · 2024Review
- Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.Ophthalmology and therapy · 2024Article
- The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD.Diagnostics (Basel, Switzerland) · 2022Article
- A Delphi study on the clinical management of age-related macular degeneration.International ophthalmology · 2022Article
- Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.Ophthalmology and therapy · 2022Article
- Article
- Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization.Scientific reports · 2021Article
- Impact of air injection on subretinal fluid following successful scleral buckling surgery for macular-involving retinal detachment.Scientific reports · 2021Article
- Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment.BMC ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD).To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat & extend anti-VEGF treatment, defined as nAMD expressing CNV exudation beyond the three monthly anti-VEGF loading doses by SRF only without any signs of exudative intra-retinal fluid (IRF) for ≥3 years. Incidence of macular atrophy and treatment responses were evaluated on multimodal imaging, including optical coherence tomography (OCT), blue autofluorescence (BAF) and near-infrared (NIR) confocal scanning laser ophthalmoscopy and fluorescence and indocyanine green angiography (FAG/ICGA). In total, 27 eyes (8.7%) of 26 patients with a mean follow-up of 4.2 ± 0.9 (3-5) years met the inclusion criteria. Mean age was 72 ± 6 (range: 61-86) years. The SRF only phenotype was seen from baseline in 14 eyes (52%), and in 13 eyes (48%) after a mean 1.0 ± 1.3 (1-3) injections. In years 1 to 5, mean 7.5, 5.9, 6.1, 6.1 and 7.0 anti-VEGF injections were given (p = 0.33). Cumulative macular atrophy incidence was 11.5% at year 1, 15.4% throughout years 2 to 4, and 22.4% at year 5. In conclusion, eyes manifesting activity by SRF only in treat & extend anti-VEGF regimen for nAMD seem to exhibit rather low rates of macular atrophy during long-term follow-up. SRF might be an indicator of a more benign form of nAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.